OrbiMed's Stake in Q32 Bio Diluted to 15.4% Following Recent Offering
QTTB has more than doubled off its 52-week low of $1.345.
Summary
OrbiMed Advisors and OrbiMed Capital GP VII LLC reported a decrease in their beneficial ownership of Q32 Bio Inc. to 15.4% due to an increase in the company's outstanding shares, reflecting the dilutive impact of a recent capital raise.
Key Events · Ownership and Investor Activity · QTTB
-
Major Shareholder Stake Reduced
OrbiMed Advisors and OrbiMed Capital GP VII LLC now beneficially own 2,252,987 shares, representing 15.4% of Q32 Bio Inc.'s common stock.
-
Dilution from Recent Offering
The decrease in percentage ownership is due to an increase in the total number of outstanding shares, resulting from the company's recent dilutive capital raise.
Analysis · QTTB · Life Sciences
This Schedule 13D/A filing updates OrbiMed's beneficial ownership in Q32 Bio Inc. The decrease in percentage ownership from an unspecified prior level to 15.4% is explicitly attributed to an increase in the number of outstanding shares, rather than a sale by OrbiMed. This change reflects the dilutive effect of the company's recent $10.5 million offering, which was reported in the 8-K and 10-K filings on March 10, 2026. While OrbiMed remains a significant shareholder, this passive dilution highlights the impact of the company's capital-raising activities on existing investor stakes.
At the time of this filing, QTTB was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103M. The 52-week trading range was $1.35 to $7.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.